OrganOmics utilizes automated microfluidic brain-on-chip technology to evaluate the pharmacological responses of candidate therapeutics in human brain tissues. This approach addresses the challenge of developing effective treatments for complex brain diseases by providing precise efficacy data for drug candidates.
Funding
Funding not disclosed
Founders
Product
Problem
Developing effective treatments for complex brain diseases is challenging due to the limitations of traditional drug screening methods, which often fail to accurately predict human responses. Existing in vitro models lack the complexity of the human brain, while in vivo studies raise ethical concerns and may not fully translate to human physiology.
Solution
OrganOmics offers an automated microfluidic brain-on-chip platform that enables the evaluation of drug candidate responses in human brain tissues. This technology provides precise efficacy data for drug candidates by mimicking the complex microenvironment of the human brain. The platform facilitates high-velocity drug discovery by enabling researchers to characterize the pharmacological response of candidate therapeutics in a more physiologically relevant context than traditional methods. By using human tissues, OrganOmics aims to bridge the gap between preclinical testing and clinical outcomes, ultimately accelerating the development of novel therapeutics for elusive brain diseases.
Target Audience
The primary customers are pharmaceutical companies, biotechnology firms, and academic research institutions involved in drug discovery and development for neurological disorders.
Features
- Automated microfluidic system for culturing and analyzing human brain tissues
- Brain-on-chip technology that replicates the in vivo brain microenvironment
- High-throughput screening capabilities for rapid drug candidate evaluation
- Real-time monitoring of cellular responses to drug treatments
- Customizable experimental parameters to model specific brain disease conditions
- Quantitative data analysis and visualization tools for assessing drug efficacy